Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG:2315)

Market Cap	41.22B +571.1%
Revenue (ttm)	1.78B +52.5%
Net Income	330.18M +536.6%
EPS	0.81 +575.2%
Shares Out	446.90M
PE Ratio	50.28
Forward PE	42.89
Dividend	n/a
Ex-Dividend Date	n/a

Volume	661,000
Open	40.10
Previous Close	40.00
Day's Range	38.54 - 42.52
52-Week Range	18.72 - 70.15
Beta	0.12
Analysts	Strong Buy
Price Target	61.98 (+51.39%)
Earnings Date	Aug 28, 2026

About HKG:2315

Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People’s Republic of China, the United States, and internationally. It operates through five segments: Gene-Editing; Pharmacological Efficacy; Model Animals; Antibody Development; and Other. The company provides the customized gene editing services based on animals and cells to meet the needs of basic science research and drug development of the customers; provid...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 1,443
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2315

Financial Performance

In 2025, HKG:2315's revenue was 1.38 billion, an increase of 40.63% compared to the previous year's 980.45 million. Earnings were 173.20 million, an increase of 416.37%.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 18, 2026

Data Sources Report a data error